BioSpace News Archive

EG 427 announces that it has received Investigational New Drug clearance from the U.S. Food and Drug Administration for EG110A, a gene therapy for the treatment of Neurogenic Detrusor Overactivity in Spinal Cord Injury patients.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces the results of the Tender Offer, as set out in the Shareholder circular published by the Company on 20 May 2024.

HUTCHMED Limited announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024.

Takeda announced that LIVTENCITY® has been approved by the Japanese Ministry of Health, Labour and Welfare for post-transplant cytomegalovirus infection/disease that is refractory to existing anti-CMV therapies

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Dr. Ian Braithwaite as Vice President, Global Project Management.

Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp.

Creative Medical Technology Holdings, Inc. announced that it has successfully generated human induced pluripotent stem cells -derived Islet Cells that produce human insulin.

Akebia Therapeutics today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer.

Bota Bio and NHU have announced the successful commercialization of their first collaborative project and the establishment of a strategic partnership to cooperate in the field of biomanufacturing.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”) today provides a corporate update following its recently announced analyses from its Phase 2b PARADIGM clinical trial, which demonstrated a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02) as compared to placebo in the pre-specified per protocol (PP) population analysis after six months of treatment.[